BAM
FDMT icon

Belpointe Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Belpointe Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,671
Closed -$37.1K – 3767
2022
Q4 		$37.1K Buy
+1,671
New +$25.8K ﹤0.01% 1789

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Belpointe Asset Management's FDMT Position: Q1 2023 in Review

Belpointe Asset Management sold out of 4D Molecular Therapeutics (FDMT) in Q1 2023, closing a stake of 1,671 shares — an estimated $37.1K sold.

Belpointe Asset Management first reported a position in FDMT in Q4 2022 and held it in 1 quarter. The position peaked at $37.1K in Q4 2022. 94 funds tracked by Wall St. Rank hold FDMT as of Q1 2023.

  • Belpointe Asset Management reported no remaining 4D Molecular Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 1,671 4D Molecular Therapeutics shares in Q1 2023, an estimated $37.1K.
  • Belpointe Asset Management first reported a position in 4D Molecular Therapeutics in Q4 2022 and held it in 1 quarter.
  • Belpointe Asset Management's 4D Molecular Therapeutics position peaked at $37.1K in Q4 2022.
  • 94 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.